The development of highly effective and durable vaccines against the human malaria
parasites Plasmodium falciparum and P. vivax remains a key priority. Decades of endeavor …

A decade of discovery and development of new anti-malarial medicines has led to a
renewed focus on malaria elimination and eradication. Changes in the way new anti …

Malaria vaccine development entered a new era in 2015 when the pre-erythrocytic
Plasmodium falciparum candidate RTS, S was favorably reviewed by the European …

Virus-like particles (VLPs) are non-infectious self-assembling nanoparticles, useful in
medicine and nanotechnology. Their repetitive molecularly-defined architecture is attractive …

Abstract Safety tested Modified Vaccinia virus Ankara (MVA) is licensed as third-generation
vaccine against smallpox and serves as a potent vector system for development of new …

Highlights•First malaria vaccine RTS, S induces anti-sporozoite antibodies to protect
children.•Whole-sporozoite vaccines induce T cells and antibodies and confer field …

BACKGROUND Vaccines that block human-to-mosquito Plasmodium transmission are
needed for malaria eradication, and clinical trials have targeted zygote antigen Pfs25 for …

Introduction Transmission-blocking vaccines (TBV) prevent community spread of malaria by
targeting mosquito sexual stage parasites, a life-cycle bottleneck, and will be used in …

The efficient spread of malaria from infected humans to mosquitoes is a major challenge for
malaria elimination initiatives. Gametocytes are the only Plasmodium life stage infectious to …

Malaria transmission-blocking vaccines (TBVs) reduce disease transmission by breaking the
continuous cycle of infection between the human host and the mosquito vector. Domain 1 …